ATAI
Price
$3.81
Change
-$0.12 (-3.05%)
Updated
Nov 19, 04:59 PM (EDT)
Capitalization
1.38B
126 days until earnings call
Intraday BUY SELL Signals
CYBN
Price
$5.93
Change
-$0.09 (-1.50%)
Updated
Nov 19, 04:59 PM (EDT)
Capitalization
305.42M
Intraday BUY SELL Signals
Interact to see
Advertisement

ATAI vs CYBN

Header iconATAI vs CYBN Comparison
Open Charts ATAI vs CYBNBanner chart's image
Atai Beckley
Price$3.81
Change-$0.12 (-3.05%)
Volume$75.46K
Capitalization1.38B
Cybin
Price$5.93
Change-$0.09 (-1.50%)
Volume$12.12K
Capitalization305.42M
ATAI vs CYBN Comparison Chart in %
ATAI
Daily Signal:
Gain/Loss:
CYBN
Daily Signal:
Gain/Loss:
View a ticker or compare two or three
VS
ATAI vs. CYBN commentary
Nov 20, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is ATAI is a Hold and CYBN is a Hold.

Interact to see
Advertisement
COMPARISON
Comparison
Nov 20, 2025
Stock price -- (ATAI: $3.93 vs. CYBN: $6.02)
Brand notoriety: ATAI and CYBN are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: ATAI: 75% vs. CYBN: 63%
Market capitalization -- ATAI: $1.38B vs. CYBN: $305.42M
ATAI [@Biotechnology] is valued at $1.38B. CYBN’s [@Biotechnology] market capitalization is $305.42M. The market cap for tickers in the [@Biotechnology] industry ranges from $106.82B to $0. The average market capitalization across the [@Biotechnology] industry is $2.15B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

ATAI’s FA Score shows that 1 FA rating(s) are green whileCYBN’s FA Score has 1 green FA rating(s).

  • ATAI’s FA Score: 1 green, 4 red.
  • CYBN’s FA Score: 1 green, 4 red.
According to our system of comparison, ATAI is a better buy in the long-term than CYBN.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

ATAI’s TA Score shows that 4 TA indicator(s) are bullish while CYBN’s TA Score has 2 bullish TA indicator(s).

  • ATAI’s TA Score: 4 bullish, 6 bearish.
  • CYBN’s TA Score: 2 bullish, 7 bearish.
According to our system of comparison, ATAI is a better buy in the short-term than CYBN.

Price Growth

ATAI (@Biotechnology) experienced а -11.29% price change this week, while CYBN (@Biotechnology) price change was -5.20% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was -2.17%. For the same industry, the average monthly price growth was -5.68%, and the average quarterly price growth was +64.91%.

Reported Earning Dates

ATAI is expected to report earnings on Mar 26, 2026.

Industries' Descriptions

@Biotechnology (-2.17% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
ATAI($1.38B) has a higher market cap than CYBN($305M). ATAI YTD gains are higher at: 186.466 vs. CYBN (-32.766). ATAI has higher annual earnings (EBITDA): -115.96M vs. CYBN (-152.51M). CYBN has more cash in the bank: 119M vs. ATAI (95.9M). ATAI has less debt than CYBN: ATAI (9.22M) vs CYBN (44.5M). ATAI has higher revenues than CYBN: ATAI (2.31M) vs CYBN (0).
ATAICYBNATAI / CYBN
Capitalization1.38B305M454%
EBITDA-115.96M-152.51M76%
Gain YTD186.466-32.766-569%
P/E RatioN/AN/A-
Revenue2.31M0-
Total Cash95.9M119M81%
Total Debt9.22M44.5M21%
FUNDAMENTALS RATINGS
ATAI vs CYBN: Fundamental Ratings
ATAI
CYBN
OUTLOOK RATING
1..100
5181
VALUATION
overvalued / fair valued / undervalued
1..100
64
Fair valued
20
Undervalued
PROFIT vs RISK RATING
1..100
8596
SMR RATING
1..100
9796
PRICE GROWTH RATING
1..100
4163
P/E GROWTH RATING
1..100
11100
SEASONALITY SCORE
1..100
5065

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

CYBN's Valuation (20) in the null industry is somewhat better than the same rating for ATAI (64) in the Miscellaneous Commercial Services industry. This means that CYBN’s stock grew somewhat faster than ATAI’s over the last 12 months.

ATAI's Profit vs Risk Rating (85) in the Miscellaneous Commercial Services industry is in the same range as CYBN (96) in the null industry. This means that ATAI’s stock grew similarly to CYBN’s over the last 12 months.

CYBN's SMR Rating (96) in the null industry is in the same range as ATAI (97) in the Miscellaneous Commercial Services industry. This means that CYBN’s stock grew similarly to ATAI’s over the last 12 months.

ATAI's Price Growth Rating (41) in the Miscellaneous Commercial Services industry is in the same range as CYBN (63) in the null industry. This means that ATAI’s stock grew similarly to CYBN’s over the last 12 months.

ATAI's P/E Growth Rating (11) in the Miscellaneous Commercial Services industry is significantly better than the same rating for CYBN (100) in the null industry. This means that ATAI’s stock grew significantly faster than CYBN’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
ATAICYBN
RSI
ODDS (%)
Bullish Trend 2 days ago
74%
Bearish Trend 2 days ago
90%
Stochastic
ODDS (%)
Bullish Trend 2 days ago
89%
Bullish Trend 2 days ago
78%
Momentum
ODDS (%)
Bearish Trend 2 days ago
89%
Bearish Trend 2 days ago
90%
MACD
ODDS (%)
Bearish Trend 2 days ago
88%
Bearish Trend 2 days ago
90%
TrendWeek
ODDS (%)
Bearish Trend 2 days ago
86%
Bearish Trend 2 days ago
90%
TrendMonth
ODDS (%)
Bearish Trend 2 days ago
88%
Bearish Trend 2 days ago
90%
Advances
ODDS (%)
Bullish Trend 24 days ago
82%
Bullish Trend 22 days ago
78%
Declines
ODDS (%)
Bearish Trend 2 days ago
86%
Bearish Trend 6 days ago
90%
BollingerBands
ODDS (%)
Bullish Trend 2 days ago
90%
Bearish Trend 2 days ago
90%
Aroon
ODDS (%)
Bearish Trend 2 days ago
88%
N/A
View a ticker or compare two or three
Interact to see
Advertisement
ATAI
Daily Signal:
Gain/Loss:
CYBN
Daily Signal:
Gain/Loss:
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
PLFPX32.75N/A
N/A
Principal Large Cap S&P 500 Index R5
ATVPX22.91N/A
N/A
Alger 35 Z
BSCRX18.28-0.02
-0.11%
Brandes Small Cap Value R6
CDWCX13.47-0.02
-0.15%
American Funds Dvlpg Wld Gr&Inc 529C
CGRWX34.06-0.14
-0.41%
Invesco Comstock Select A

ATAI and

Correlation & Price change

A.I.dvisor indicates that over the last year, ATAI has been loosely correlated with MNMD. These tickers have moved in lockstep 50% of the time. This A.I.-generated data suggests there is some statistical probability that if ATAI jumps, then MNMD could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To ATAI
1D Price
Change %
ATAI100%
-3.05%
MNMD - ATAI
50%
Loosely correlated
-4.29%
COUR - ATAI
45%
Loosely correlated
-1.10%
VCYT - ATAI
45%
Loosely correlated
+3.02%
CYBN - ATAI
39%
Loosely correlated
-1.50%
RXRX - ATAI
38%
Loosely correlated
-3.12%
More

CYBN and

Correlation & Price change

A.I.dvisor indicates that over the last year, CYBN has been loosely correlated with ATAI. These tickers have moved in lockstep 39% of the time. This A.I.-generated data suggests there is some statistical probability that if CYBN jumps, then ATAI could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To CYBN
1D Price
Change %
CYBN100%
-1.50%
ATAI - CYBN
39%
Loosely correlated
-3.05%
ABSI - CYBN
36%
Loosely correlated
+0.70%
RXRX - CYBN
34%
Loosely correlated
-3.12%
EYPT - CYBN
33%
Loosely correlated
+2.29%
SYRE - CYBN
31%
Poorly correlated
+0.83%
More